|Bid||70.79 x 900|
|Ask||71.99 x 1300|
|Day's range||69.47 - 72.30|
|52-week range||32.95 - 72.30|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||N/A|
|Earnings date||05 Nov 2020 - 09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||83.23|
Amit Munshi became the CEO of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in 2016, and we think it's a good time to look...
If you want to know who really controls Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), then you'll have to look at the...
Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are up 13% at 2:13 p.m. EDT because its rival, Bristol Myers Squibb (NYSE: BMY), reported positive data on Zeposia in patients with ulcerative colitis. Zeposia targets the sphingosine-1-phosphate (S1P) receptor, just like Arena's etrasimod. Typically, good data from a rival drugmaker would send shares down, not up, but ulcerative colitis is a common enough disease -- around a million Americans have it -- that there's enough room in the marketplace for more than one drug.